Medication Screening
Cardiovascular Health
- Regular price
-
$299 - Regular price
-
- Sale price
-
$299
Save 20% applied at checkout
Personalized genetic insights to help you find the right heart medications
Inagene’s new cardiology test offers personalized genetic insights into how your body responds to critical heart medications.
Couldn't load pickup availability
Split your purchase into 3 monthly payments at check out
Medications tested
We test for 49 critical medications, including many that treat high cholesterol, thin blood, directly impact the functioning of the heart, and more.
Shipping information
Canada & US: Free shipping on your order and free return shipping for your swab. A prepaid return label is included in your package.
International: Free shipping to you but return shipping for your swab is not included.
Powerful genetic insights
We use the world’s best science to help you limit trial and error, avoid side effects, and find the right medications faster.
Prevent heart attacks and strokes
Optimize critical treatment for cholesterol, blood thinning and heart function used to prevent serious cardiovascular events, with better doses and medications because they're tailored to your genetics.
Avoid side effects
By understanding your unique genetic profile you can avoid unnecessary side effects and improve the effectiveness of prescribed medications. Pharmacogenetic testing can help reduce the risk of side effects by 30%.¹
Are statins right for you?
12% of Canadians aged 20-79² have reported taking statins, yet only 25-40% of older adults continue taking their statins as prescribed after 2 years of starting them³. Individuals often stop their statins due to side effects like muscle pain.
Case Study:
-
A commonly prescribed blood thinner
-
Clopidogrel, known as Plavix in many countries, is a commonly prescribed blood thinner for preventing recurrent strokes and heart attacks. Research has consistently shown that a specific gene (known as CYP2C19) significantly influences the drug's effectiveness. Everyone has two versions of this gene (one from each parent), and the combination, or "genotype", plays a significant role in the medication's effectiveness.
Pharmacogenetic testing has found these cases in which clopidogrel is not likely to be effective:
-
39%
of African-Americans and Afro-Caribbeans
-
23%
of Americans
-
49%
of Central and South Asians
-
59%
of East Asians
-
29%
of Europeans
-
21%
of Latinos
-
25%
of Near Easterners
-
39%
of Sub-Saharan Africans
-
94%
of Oceanians
If clopidogrel is ineffective, it significantly increases the risk of recurrent strokes or heart attacks, highlighting the importance of pharmacogenetic testing for personalized medication management.
Adapted from supplement to: Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526
How It Works
It starts with a simple cheek swab test at home
-
Swab your cheek with our kit and mail it to our lab with the package provided.
-
When your results are ready, view, download and share your personalized insights.
-
Discuss your results with your healthcare provider to optimize your treatment plan.
Your Inagene Insights
Your Inagene insights provide a personalized guide detailing how your genetic information can affect your body’s response to medications. They deliver clear recommendations so you and your healthcare team can make informed decisions about medications. The insights categorize medications based on the detection of specific genetic variants known to impact individual responses to drugs:
-
Consider Alternatives
Genetic variant(s) potentially impacting response to this medication were identified. This medication may not be appropriate. Consult the “detailed recommendations” section of the report for details.
-
Consider Modified Approach
Genetic variant(s) potentially impacting response to this medication were identified. Consult the “detailed recommendations” section of the report for details.
-
Use Standard Precautions
No genetic variants impacting response to this medication were identified.
-
Use Standard Precautions (Preferred)
Genetic variant(s) potentially improving response to this medication were identified. Consult the “detailed recommendations” section of the report for details.
Your privacy is our top priority
Learn More
FAQ
Where do the recommendations in the report come from?
The recommendations in Inagene's report are sourced from several established expert pharmacogenetics consortia, and regulatory bodies like the FDA. These recommendations are then paired with insights gleaned from your DNA profile to provide you with personalized insights that can help you feel better, sooner.
Which conditions does the test cover?
Your Inagene report provides information related to your predicted response to medications used in a variety of therapeutic areas. Our tests cover mental health (depression, anxiety PTSD, OCD and more), cardiology, gastroenterology, neurology, oncology, postpartum, pregnancy, menopause and more. Applicability of your results will depend on your specific condition(s) and circumstances. Only your health care provider can determine if and how results can be applied to your treatment plan. View our full list of medications.
How will my Inagene report help me get better healthcare?
Your personalized report will allow you and your health care team to manage your health concerns more effectively and safely. By analyzing your DNA, we can predict how you will respond to up to 196 commonly used medications. Your Inagene report offers personalized recommendations on which medications could work better for you, which medications may need to be prescribed using a modified approach, and when alternative medications should be considered. The recommendations in your report will help you reduce side effects, avoid trial and error and find a more effective medication faster.
-
References
-
- Swen JJ, van der Wouden CH, Manson LE, et al.
- Statistics Canada
- Jackevicius CA, Mamdani M, Tu JV
- Adapted from supplement to: Lee CR, Luzum JA, Sangkuhl K, et al
